Gilead Sciences, Inc. (GILD) income statement
NASDAQ · Healthcare · Drug Manufacturers - General · 17,000 employees · CEO Daniel O'Day
- Price
- $170.68 +3.06%
- Market cap
- $212B
- Enterprise value
- $231B
- Last report
- Q3 '26 filed 2026-10-30
- Next report
- 2027-02-09 EPS est. $1.39
Gilead Sciences, Inc. (GILD) reported revenue of $8.3B for Q3 '26 (+6.8% year on year), operating income of $3.46B (41.7% of revenue) and net income of $2.43B. Over the last four quarters revenue was $31B.
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.11B | $6.69B | $6.95B | $7.55B | $7.57B | $6.67B | $7.08B | $7.77B | $7.92B | $6.96B | $7.8B | $8.3B | |
| Cost of revenue | $2.09B | $1.55B | $1.54B | $1.57B | $1.58B | $1.54B | $1.5B | $1.57B | $1.62B | $1.45B | $1.58B | $1.57B | |
| Gross profit | $5.02B | $5.13B | $5.41B | $5.97B | $5.99B | $5.13B | $5.58B | $6.2B | $6.3B | $5.52B | $6.22B | $6.73B | |
| Research & development | $1.41B | $1.52B | $1.35B | $1.4B | $1.64B | $1.38B | $1.49B | $1.35B | $1.58B | $1.37B | $1.76B | $1.61B | |
| Sales & marketing | $826M | $743M | $805M | $968M | $869M | $753M | $864M | $829M | $1.08B | $898M | $0 | $946M | |
| General & administrative | $754M | $632M | $572M | $442M | $992M | $505M | $501M | $528M | $652M | $553M | $0 | $695M | |
| Other operating expenses | $424M | $6.56B | $37M | $2.28B | $34M | $253M | $250M | $170M | $0 | $106M | $12.9B | $18M | |
| Operating expenses | $3.41B | $9.46B | $2.77B | $5.08B | $3.54B | $2.89B | $3.11B | $2.87B | $3.31B | $2.93B | $16.6B | $3.27B | |
| Operating income | $1.61B | -$4.32B | $2.64B | $888M | $2.45B | $2.24B | $2.47B | $3.33B | $2.99B | $2.59B | -$10.4B | $3.46B | |
| Interest income | $0 | $108M | $35M | $52M | $85M | $94M | $73M | $88M | $95M | $0 | $0 | $41M | |
| Interest expense | $252M | $254M | $237M | $238M | $249M | $260M | $254M | $256M | $255M | $240M | $247M | $269M | |
| Other non-operating income (gains on investments, FX ...) | -$293M | -$90M | $354M | -$306M | $36M | $328M | -$209M | -$570M | $655M | $235M | -$387M | $130M | |
| Total non-operating income | $41M | -$164M | -$591M | $68M | -$285M | -$588M | -$45M | $314M | -$910M | -$6M | $140M | -$399M | |
| Income before tax | $1.65B | -$4.49B | $2.05B | $956M | $2.17B | $1.65B | $2.43B | $3.64B | $2.08B | $2.58B | -$10.3B | $3.06B | |
| Income tax | $237M | -$315M | $438M | -$297M | $385M | $334M | $468M | $589M | -$105M | $559M | $242M | $634M | |
| Net income | $1.43B | -$4.17B | $1.61B | $1.25B | $1.78B | $1.32B | $1.96B | $3.05B | $2.18B | $2.02B | -$10.5B | $2.43B | |
| EPS (basic) | $1.15 | -$3.34 | $1.29 | $1.00 | $1.43 | $1.06 | $1.57 | $2.46 | $1.76 | $1.63 | -$8.45 | $1.96 | |
| EPS (diluted) | $1.14 | -$3.34 | $1.29 | $1.00 | $1.42 | $1.04 | $1.56 | $2.43 | $1.74 | $1.61 | -$8.45 | $1.94 | |
| Shares (basic, weighted) | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.24B | 1.24B | 1.24B | 1.24B | 1.24B | |
| Shares (diluted, weighted) | 1.26B | 1.25B | 1.25B | 1.25B | 1.26B | 1.26B | 1.26B | 1.25B | 1.25B | 1.25B | 1.24B | 1.25B | |
| Depreciation & amortization | $688M | $690M | $694M | $690M | $693M | $696M | $691M | $686M | $687M | $689M | $698M | $740M | |
| EBITDA | $2.59B | -$3.54B | $2.98B | $1.88B | $3.11B | $2.61B | $3.37B | $4.58B | $3.02B | $3.04B | -$9.31B | $4.07B |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.4B | $26.1B | $22.1B | $22.4B | $24.7B | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B | |
| Cost of revenue | $4.26B | $4.37B | $4.85B | $4.68B | $4.57B | $6.6B | $5.66B | $6.5B | $6.25B | $6.23B | |
| Gross profit | $26.1B | $21.7B | $17.3B | $17.8B | $20.1B | $20.7B | $21.6B | $20.6B | $22.5B | $23.2B | |
| Research & development | $5.1B | $3.73B | $3.92B | $4.06B | $5.04B | $4.6B | $4.98B | $5.72B | $5.91B | $5.8B | |
| Sales & marketing | $0 | $0 | $0 | $0 | $795M | $735M | $778M | $3.27B | $3.45B | $3.52B | |
| General & administrative | $0 | $0 | $0 | $0 | $4.32B | $4.51B | $4.9B | $2.82B | $2.64B | $2.19B | |
| Other operating expenses | $0 | $0 | $0 | $0 | $5.9B | $939M | $3.64B | $1.21B | $8.84B | $0 | |
| Operating expenses | $8.5B | $7.61B | $7.98B | $8.44B | $16B | $10.8B | $14.3B | $13B | $20.8B | $11.5B | |
| Operating income | $17.6B | $14.1B | $8.2B | $4.29B | $4.07B | $9.92B | $7.33B | $7.61B | $1.66B | $11.7B | |
| Interest income | $0 | $0 | $0 | $0 | $0 | $0 | $106M | $376M | $281M | $349M | |
| Interest expense | $964M | $1.12B | $1.08B | $995M | $984M | $1B | $935M | $944M | $977M | $1.02B | |
| Other non-operating income (gains on investments, FX ...) | -$428M | -$523M | -$676M | -$1.87B | $1.42B | $639M | $581M | -$198M | -$5M | $881M | |
| Total non-operating income | -$536M | -$595M | -$401M | $873M | -$2.4B | -$1.64B | -$1.52B | -$746M | -$972M | -$1.91B | |
| Income before tax | $17.1B | $13.5B | $7.8B | $5.16B | $1.67B | $8.28B | $5.81B | $6.86B | $690M | $9.8B | |
| Income tax | $3.61B | $8.89B | $2.34B | -$204M | $1.58B | $2.08B | $1.25B | $1.25B | $211M | $1.29B | |
| Net income | $13.5B | $4.63B | $5.46B | $5.39B | $123M | $6.23B | $4.59B | $5.67B | $480M | $8.51B | |
| EPS (basic) | $10.08 | $3.54 | $4.20 | $4.24 | $0.10 | $4.96 | $3.66 | $4.54 | $0.38 | $6.84 | |
| EPS (diluted) | $9.94 | $3.51 | $4.17 | $4.22 | $0.10 | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 | |
| Shares (basic, weighted) | 1.34B | 1.31B | 1.3B | 1.27B | 1.26B | 1.26B | 1.26B | 1.25B | 1.25B | 1.24B | |
| Shares (diluted, weighted) | 1.36B | 1.32B | 1.31B | 1.28B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | |
| Depreciation & amortization | $1.16B | $1.29B | $1.43B | $1.4B | $1.48B | $2.05B | $2.1B | $2.69B | $2.77B | $2.76B | |
| EBITDA | $19.2B | $15.9B | $10.3B | $7.56B | $4.13B | $11.3B | $8.85B | $10.5B | $4.43B | $13.6B |
Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data as of 2026-11-01